Altasciences Featured Content

  1. Streamlining Study Start-Up For Accelerated Drug Development 2/20/2024

    What is the secret to safely expediting study start-ups? Explore our case study to find out how open dialogue, aligned expectations, and direct communication between Altasciences’ team leads and sponsor contributed to a clinical trial start-up of only 3.5 weeks.

  2. Flexibility In Phase 1 Study Timing 1/26/2024

    Combining certain Phase 2 studies with the Phase 1 protocol gives you earlier access to data, enabling more informed go/no-go decisions early in the program. This strategy makes it possible to accelerate drug development and better allocate resources.

  3. The Advantages Of Conducting Early-Phase Clinical Trials In Canada 7/5/2023

    By completing your trials in Canada, you can accelerate your early phase clinical research by six to nine weeks compared to an IND submission in the U.S.

  4. Shortening Drug Development Timelines With Asian Ethnobridging Trials 1/26/2024

    Learn how Asian ethnobridging trials in Phase 1 demonstrate PK similarity and help cut years off global drug development timelines.

  5. The Importance Of Diversity In Clinical Trials 10/16/2024

    A recent FDA draft guidance aims to address health disparities and enhance data quality with action plans for greater inclusivity in clinical trials. Explore practical steps to building trust and inclusivity in clinical research.

  6. First-in-Human Solutions for Small and Large Molecules 10/9/2026

    Understand how an integrated approach to first-in-human studies can support small and large molecule programs through efficient execution and informed development decisions.

  7. Does Your Drug Require A Driving Study? Find Out What The FDA Says. 5/9/2025

    Some CNS drugs need to be assessed for their impact on driving ability. Driving simulation studies offer faster startup, lower cost, and no safety risk. Learn more and discover a real-life case study.

  8. Canadian CTA Frequently Asked Questions 2/20/2024

    This FAQ list offers clarity on pivotal aspects of your drug development journey, ensuring studies in Canada pave the way for U.S. FDA and EMA submissions.

  9. Navigating The Complexities Of CNS-Active Drugs 5/9/2025

    In this article, we provide a detailed overview of the multiple facets you need to consider during the planning and conduct of your CNS-active drug development.

  10. The Complexities Of Early Phase Ophthalmic Drug Development 1/26/2023

    Discover how the complexity and challenges of bringing ophthalmic therapeutics to market can be mitigated by entrusting your drug development program to an integrated CRO/CDMO partner.